DMKPQ: AI 评分 61/100 — AI 分析 (4月 2026)

DMK Pharmaceuticals Corporation is a clinical-stage neuro-biotechnology company focused on developing and commercializing products for allergy, opioid overdose, respiratory, and inflammatory diseases. The company filed for Chapter 11 reorganization in February 2024.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals, is a clinical-stage neuro-biotechnology company developing therapies for allergy, opioid overdose, and respiratory conditions. Currently undergoing Chapter 11 reorganization, DMKPQ navigates a competitive landscape with products like SYMJEPI and ZIMHI, while focusing on its lead candidate DPI-125 for opioid use disorder.

DMKPQ是做什么的？

DMK Pharmaceuticals Corporation, previously known as Adamis Pharmaceuticals Corporation until its name change in September 2023, is a clinical-stage neuro-biotechnology company dedicated to developing and commercializing products targeting allergy, opioid overdose, respiratory, and inflammatory diseases. Founded with the mission of addressing unmet medical needs, the company is headquartered in San Diego, California. DMK's portfolio includes SYMJEPI, an epinephrine injection for emergency treatment of allergic reactions, and ZIMHI, a naloxone injection designed to combat opioid overdose. The company's pipeline is anchored by DPI-125, a clinical-stage product candidate aimed at treating opioid use disorder. DMK Pharmaceuticals has navigated a challenging path, culminating in a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024. This strategic move aims to restructure the company's finances and operations to ensure long-term sustainability. Despite the financial headwinds, DMK remains committed to advancing its therapeutic programs and delivering innovative solutions to patients in need. The company's focus on specialized areas like allergy and opioid overdose positions it within a critical segment of the healthcare industry, addressing significant public health concerns.

DMKPQ的投资论点是什么？

DMK Pharmaceuticals Corporation presents a high-risk, high-reward investment profile, particularly given its Chapter 11 reorganization filing in February 2024. The company's value hinges on the successful restructuring and advancement of its lead clinical candidate, DPI-125, targeting opioid use disorder. Key value drivers include potential FDA approval for DPI-125 and successful commercialization of existing products like SYMJEPI and ZIMHI post-reorganization. However, the company's negative profit margin of -556.7% and gross margin of -60.9% underscore significant financial challenges. Upcoming milestones include navigating the bankruptcy process and securing funding for continued operations and clinical trials. Investors should closely monitor the company's progress in restructuring its debt and achieving operational efficiency.

DMKPQ在哪个行业运营？

DMK Pharmaceuticals Corporation operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The market for opioid overdose treatments and allergy therapies is substantial, driven by increasing prevalence and public health initiatives. DMK's competitors include companies like ADLI, AMHD, BIMI, CFRXQ, and EFTR. The industry is witnessing a growing emphasis on innovative drug delivery systems and personalized medicine, with companies striving to differentiate themselves through novel formulations and targeted therapies. DMK's success depends on its ability to navigate regulatory hurdles, secure funding, and effectively commercialize its products in a dynamic market.

Drug Manufacturers - Specialty & Generic

Healthcare

DMKPQ有哪些增长机遇？

Advancement of DPI-125: DMK's lead clinical candidate, DPI-125, targets opioid use disorder, a market projected to reach billions of dollars. Successful completion of clinical trials and FDA approval could significantly boost DMK's revenue and market share. The timeline for potential approval is dependent on the Chapter 11 reorganization and subsequent funding for clinical trials.
Expansion of SYMJEPI Market: SYMJEPI, an epinephrine injection for allergic reactions, has the potential for increased market penetration. The global epinephrine market is expected to grow, driven by rising allergy rates. DMK can capitalize on this trend by expanding its distribution network and increasing awareness of SYMJEPI's benefits. This expansion is contingent on the company's financial restructuring.
Strategic Partnerships: DMK can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its products. These partnerships can provide access to additional funding, expertise, and distribution channels. The timeline for securing such partnerships depends on DMK's ability to demonstrate the value of its pipeline and products.
Geographic Expansion: DMK can expand its geographic reach by entering new markets outside the United States. This expansion can increase its customer base and revenue streams. The timeline for international expansion is dependent on regulatory approvals and market entry strategies.
Acquisition of Complementary Assets: DMK can acquire complementary assets or technologies to expand its product portfolio and capabilities. These acquisitions can enhance its competitive position and drive long-term growth. The feasibility of acquisitions is contingent on the company's financial restructuring and access to capital.

Market capitalization of $0.00B reflects the company's current financial distress and Chapter 11 status.
Negative Profit Margin of -556.7% indicates substantial losses and operational inefficiencies.
Gross Margin of -60.9% highlights challenges in pricing and cost management for its products.
Beta of 0.79 suggests lower volatility compared to the overall market.
No dividend is currently offered, reflecting the company's focus on reinvesting capital into its operations and restructuring efforts.

DMKPQ提供哪些产品和服务？

Develops and commercializes products for allergy, opioid overdose, respiratory, and inflammatory diseases.
Offers SYMJEPI epinephrine injection for emergency treatment of allergic reactions.
Provides ZIMHI naloxone injection for the treatment of opioid overdose.
Focuses on DPI-125, a clinical-stage product candidate for opioid use disorder.
Engages in research and development of neuro-biotechnology therapies.
Aims to address unmet medical needs in specialized therapeutic areas.

DMKPQ如何赚钱？

Develops pharmaceutical products through research and clinical trials.
Seeks regulatory approval from agencies like the FDA.
Manufactures and markets its approved products.
Generates revenue through product sales.

Patients requiring emergency treatment for allergic reactions.
Individuals suffering from opioid overdose.
Healthcare providers prescribing allergy and opioid overdose treatments.
Hospitals and clinics administering emergency medications.

Proprietary formulations and drug delivery systems.
Patent protection for its key products and technologies.
Established brand recognition for SYMJEPI and ZIMHI.
Specialized expertise in allergy and opioid overdose therapies.

什么因素可能推动DMKPQ股价上涨？

Upcoming: Successful navigation of Chapter 11 bankruptcy proceedings by the end of 2026.
Upcoming: Potential FDA approval and commercialization of DPI-125 for opioid use disorder, timeline dependent on funding.
Ongoing: Strategic partnerships with larger pharmaceutical companies to co-develop and commercialize products.
Ongoing: Expansion of SYMJEPI market share through increased distribution and awareness.
Ongoing: Continued research and development efforts to expand product pipeline.

DMKPQ的主要风险是什么？

Ongoing: Chapter 11 bankruptcy poses a significant threat to the company's survival.
Potential: Regulatory hurdles and delays in product approvals could impede commercialization.
Potential: Intense competition from established pharmaceutical companies may limit market share.
Potential: Product liability claims and litigation risks associated with pharmaceutical products.
Potential: Changes in healthcare policies and reimbursement rates could impact revenue.

DMKPQ的核心优势是什么？

Specialized product portfolio in allergy and opioid overdose.
Established brand recognition for SYMJEPI and ZIMHI.
Clinical-stage product candidate DPI-125 with potential for significant revenue.
Experienced management team with expertise in drug development.

DMKPQ的劣势是什么？

Chapter 11 bankruptcy filing indicates severe financial distress.
Negative profit and gross margins reflect operational inefficiencies.
Limited financial resources for research and development.
Dependence on regulatory approvals for product commercialization.

DMKPQ有哪些机遇？

Growing market for opioid overdose treatments and allergy therapies.
Potential for strategic partnerships with larger pharmaceutical companies.
Expansion into new geographic markets.
Acquisition of complementary assets or technologies.

DMKPQ面临哪些威胁？

Intense competition from established pharmaceutical companies.
Regulatory hurdles and delays in product approvals.
Product liability claims and litigation risks.
Changes in healthcare policies and reimbursement rates.

DMKPQ的竞争对手是谁？

Adial Pharmaceuticals, Inc. — Focuses on therapies for addiction. — (ADLI)
American Health Products, Inc. — Offers a range of health and wellness products. — (AMHD)
BIMI International Medical Inc. — Operates in the healthcare products and services sector. — (BIMI)
ContraFect Corporation — Develops therapies for infectious diseases. — (CFRXQ)
Elefteria Labs, Inc. — Focuses on cannabinoid-based health and wellness products. — (EFTR)

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: Eddie Wabern Glover
Headquarters: San Diego, US
Employees: 11
Founded: 1995

AI Insight

AI analysis pending for DMKPQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does DMK Pharmaceuticals Corporation do?

DMK Pharmaceuticals Corporation is a clinical-stage neuro-biotechnology company focused on developing and commercializing pharmaceutical products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. Its key products include SYMJEPI, an epinephrine injection for allergic reactions, and ZIMHI, a naloxone injection for opioid overdose. The company's lead clinical candidate, DPI-125, targets opioid use disorder. Currently undergoing Chapter 11 reorganization, DMK aims to restructure its finances and operations to ensure long-term sustainability and advance its therapeutic programs.

What do analysts say about DMKPQ stock?

AI analysis is currently pending for DMKPQ. Given the company's Chapter 11 bankruptcy filing and OTC Other listing, traditional analyst coverage may be limited. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in distressed companies. Key valuation metrics are currently negative due to the company's financial challenges. Growth considerations hinge on the successful restructuring and advancement of its clinical pipeline, particularly DPI-125.

What are the main risks for DMKPQ?

The primary risk for DMK Pharmaceuticals Corporation is its Chapter 11 bankruptcy filing, which introduces significant uncertainty regarding the company's future viability. Additional risks include regulatory hurdles and delays in product approvals, intense competition from established pharmaceutical companies, product liability claims, and changes in healthcare policies and reimbursement rates. Investing in OTC Other stocks like DMKPQ carries inherent risks due to limited financial disclosure and low trading volume.